Windlas Biotech (WINDLAS) — Announcement

📢 Key Event
Windlas Biotech posted robust Q1 FY27 growth with 18% revenue increase and 37% PAT growth.

🔄 What Changed
Revenue growth accelerated to 18% YoY and PAT growth to 37% YoY versus prior periods

💡 Investor Takeaway
Shareholders benefit from strong growth, healthy margins, and consistent capital returns amid expanding global markets.

Windlas Biotech reported 18% YoY revenue growth to Rs 248 crore in Q1 FY27, driven by 84% contribution from its Generic Formulations CDMO segment, with exports surging 79% to Rs 11 crore. Adjusted EBITDA rose 26% to Rs 34 crore and adjusted PAT grew 37% to Rs 25 crore, supported by Rs 251 crore net liquidity and an A+ ICRA rating. The company completed a Rs 47 crore buyback without promoter participation and declared a Rs 13 crore dividend for FY26, reflecting strong cash generation and shareholder-friendly capital allocation.

📄 View Original Announcement (PDF)

📊 Stock Analysis — WINDLAS ✨ Ask AI About This

About Windlas Biotech Limited (WINDLAS)

Healthcare · Pharmaceuticals & Biotechnology · Listed on NSE

Market Cap: ₹1,645.02 Cr P/E: 26.4

View full WINDLAS stock details →

📡 Get AI alerts when WINDLAS files next

Free • Daily 5 PM digest • Track filings, board meetings, and corporate actions

Track WINDLAS — Free

💡 Ask AI about this filing

"How does export growth compare to peers?" "What is the valuation multiple?" "When will next dividend be announced?"

Ask AI Free →

📊 More WINDLAS filings

See all WINDLAS filings →

🔥 Also filed on 10 August 2026

TIMKEN Timken India Limited Financial Results AMJLAND Amj Land Holdings Limited Annual Report DOMS DOMS Industries Limited Corporate Action HGS Hinduja Global Solutions Limited Financial Results SUNDRMFAST Sundram Fasteners Limited Financial Results KANSAINER Kansai Nerolac Paints Limited Financial Results

View all today's announcements →

Source: Stock Announcements. Analysis by StockFin.ai. For informational purposes only — not investment advice.

Editorial & Data Transparency Notice

This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.

📡 Get AI alerts when WINDLAS files new disclosures

Track WINDLAS filings, board meetings, and corporate actions. Free email alerts at 5 PM.